Cooley M&A

JANUARY 25, 2023

But it wasn’t all carve outs and concerned investors – even with the headwinds in the industry and beyond, there were still several traditional public M&A deals involving biotechnology or medical device companies, as large pharmaceutical companies continued to have cash to deploy for acquisitions. Let’s dig in.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Cooley M&A

JANUARY 23, 2024

While the year saw an overall decline in M&A activity (down 17% from 2022) , total pharmaceuticals and life sciences deal value in 2023 increased by approximately 50% compared to 2022. Why did life sciences outperform the market? The last quarter of the year ended with a surge of deal activity.

M&A 52

M&A Mergers and Acquisitions Pharmaceutical Acquisitions 52

Peak Frameworks

SEPTEMBER 19, 2023

For example, in the 2012 Facebook IPO, common shareholders gained exposure to the tech giant's fortunes, while also securing a say in corporate matters. Types of Shareholders: Common Shareholders : These individuals hold common shares, entitling them to voting rights and dividends.

Corporation 52

Corporation Private Equity Mergers and Acquisitions Corporate Finance 52

M&A Leadership Council

JUNE 12, 2023

Also, I find it’s helpful to remind deal leaders and business sponsors that every organization has a different definition of what is traditionally called IT, for example, core platform, shared services, network, infrastructure, applications, data, security, etc. All businesses need to be digital businesses these days.

IT 52

IT M&A Securities Insurance 52

M&A Leadership Council

SEPTEMBER 9, 2021

Also, I find it’s helpful to remind deal leaders and business sponsors that every organization has a different definition of what is traditionally called IT, for example, core platform, shared services, network, infrastructure, applications, data, security, etc. All businesses need to be digital businesses these days.

IT 52

IT M&A Securities Insurance 52

Cooley M&A

JANUARY 20, 2022

1] Major all-cash acquisitions have followed, such as Arena Pharmaceutical’s agreement to sell to Pfizer for $6.7 Midsize pharmaceutical buyers pursuing opportunistic acquisition strategies, with robust capital markets and high valuations having limited the pool of attractive assets available in recent years. time highs in 2021.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Mergers 40